Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RUCAPARIB CAMSYLATE vs RUXOLITINIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RUCAPARIB CAMSYLATE vs RUXOLITINIB: Safety Overview

Metric RUCAPARIB CAMSYLATE RUXOLITINIB
Total FAERS Reports 8,240 68,133
Deaths Reported 448 10,908
Death Rate 5.4% 16.0%
Hospitalizations 1,148 14,461
Average Patient Age 65.1 yrs 59.7 yrs
% Female Patients 95.2% 48.8%
FDA Approval Date Dec 19, 2016 Nov 16, 2011
Manufacturer pharmaand GmbH Incyte Corporation
Route ORAL TOPICAL
Marketing Status Prescription Prescription